🔴 SAB Biotherapeutics is trading 5% down today with biotech-sector weakness the likeliest context

SAB Biotherapeutics is trading at $2.94, down 5.16%, with biotech-sector weakness the likeliest context; available evidence does not establish a direct cause.

• No clear company-specific catalyst was found for October 6; the latest company announcement was October 1, about presenting SAB-142 data.
• The provided sector update put XBI down 2.50%, while market data also showed substantial intraday declines.
• The broader U.S. market was higher, so the decline appears more consistent with sector pressure than general market sentiment.